Drugs / CMN-001
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04203901 | Jul 2020 → Sep 2023 | renal cell carcinoma | CoImmune | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMN-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04203901 ↗ |
| Modality | Cell therapy | “CMN-001 is an autologous, tumor antigen-loaded dendritic cell immunotherapy.” NCT04203901 ↗ |